Business Context and Reporting Period
Company: BridgeBio Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 13, 2021
Event: Entry into a Material Definitive Agreement (Sixth Amendment to Loan and Security Agreement).
Key Financial Metrics and Debt Structure
This filing details a restructuring of the Company's credit facility with Hercules Capital, Inc. as the administrative agent. The filing does not provide current revenue, profit, cash flow, or margin data.
| Debt Component | Amount / Terms |
|---|---|
| Existing Principal Balance | $100,000,000 (Composed of $35M, $20M, $20M, and $25M tranches) |
| Interest Rate | Greater of (Prime Rate + 4.40%) or 7.65% |
| Interest-Only Period | Extended to June 1, 2024 (potentially extendable to June 1, 2025) |
| Maturity Date | Extended to May 1, 2025 (potentially extendable to May 1, 2026) |
| Available Incremental Loans | $70,000,000 (by June 15, 2022) |
| Milestone Incremental Loan | $40,000,000 (by Sept 15, 2022, subject to performance) |
| Discretionary Incremental Tranche | $75,000,000 (by Dec 15, 2023, subject to lender approval) |
Material Changes Versus Prior Period
- Term Extension: The maturity date for term loans was extended from the original schedule to May 1, 2025, with an option to extend to May 1, 2026.
- Payment Deferral: The interest-only period was extended to June 1, 2024, delaying principal repayment obligations.
- Increased Liquidity Capacity: The agreement provides access to up to $185,000,000 in additional incremental funding, contingent on dates, milestones, or lender discretion.
- Debt Flexibility: The amendment grants greater flexibility to incur or repurchase convertible debt.
Guidance, Outlook, and Risks
Management Commentary: The amendment is designed to provide the Company with extended time horizons for repayment and increased access to capital to support operations and potential milestones.
Risks and Contingencies:
- Conditional Funding: The $40 million milestone tranche and $75 million discretionary tranche are not guaranteed and depend on performance metrics or Hercules Capital's sole discretion.
- Interest Rate Exposure: The interest rate is variable (linked to the prime rate) but includes a 7.65% floor.
- Future Filings: The full text of the Credit Agreement Amendment will be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2021.
Investor Verification Checklist
- Verify the exact terms of the "performance milestones" required to unlock the $40 million incremental loan.
- Confirm the current outstanding principal balance and accrued interest as of the filing date.
- Review the upcoming Form 10-Q (due for the quarter ending June 30, 2021) for the full text of the Credit Agreement Amendment.
- Assess the Company's cash burn rate relative to the extended interest-only period ending June 2024.